Bora Pharmaceuticals CoTPE:6472 +1.74%87 EV-to-FCF is 20.35 as of Jul. 05, 2026, which is 9% above its 10-year median of 18.75. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$716.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 561 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 51.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bora Pharmaceuticals Co's Enterprise Value is NT$71,166 Mil.
Bora Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$3,497 Mil. Therefore, Bora Pharmaceuticals Co's EV-to-FCF for today is 20.35.
The historical rank and industry rank for Bora Pharmaceuticals Co's EV-to-FCF or its related term are showing as below:
TPE:6472'
s EV-to-FCF Range Over the Past 10 Years
Min: -773.37 Med: 18.75 Max: 507.94
Current: 20.35
During the past 13 years, the highest EV-to-FCF of Bora Pharmaceuticals Co was 507.94. The lowest was -773.37. And the median was 18.75.
TPE:6472's EV-to-FCF is ranked better than 51.16% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs TPE:6472: 20.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bora Pharmaceuticals Co (TPE:6472) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bora Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Bora Pharmaceuticals Co's share price for today is NT$439.50.
Bora Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$23.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's EV-to-FCF falls into.
Bora Pharmaceuticals Co's current Enterprise Value is NT$71,166 Mil.
Bora Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,497 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (TPE:6472) has a EV-to-FCF of 20.35 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bora Pharmaceuticals Co and its competitors. This is near median its historical median of 18.75. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #274 out of 561 companies in the Drug Manufacturers industry, placing it in the top 48.8%.
Is Bora Pharmaceuticals Co's EV-to-FCF too high?
Bora Pharmaceuticals Co's current EV-to-FCF of 20.35 is near median its 10-year median of 18.75. The Drug Manufacturers industry median EV-to-FCF is 20.85. Bora Pharmaceuticals Co's value of 20.35 is 2.4% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #274 out of 561 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #274 out of 561 companies for EV-to-FCF. This puts Bora Pharmaceuticals Co in the upper half of its industry. The industry median EV-to-FCF is 20.85. Bora Pharmaceuticals Co's value of 20.35 is 2.4% below this benchmark. While the company's 10-year median is 18.75 vs. the industry median of 20.85, Bora Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current EV-to-FCF of 20.35 is 2.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current EV-to-FCF is 20.35, which is near median its own 10-year median of 18.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$716.94, compared to a current price of NT$439.50 — trading 38.7% below its estimated fair value. The current EV-to-FCF is 20.35, which is near median its 10-year median of 18.75 and 2.4% below the Drug Manufacturers industry median of 20.85. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current EV-to-FCF is 20.35 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$439.50 is trading 38.7% below its estimated GF Value™ of NT$716.94.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
EV-to-FCF: 20.35 (near median its 10-year median of 18.75)
GF Value™: NT$716.94 vs. price of NT$439.50 (38.7% below fair value)
Industry Position: 2.4% below the Drug Manufacturers median (#274 of 561)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
